Overview
Sustainable Solutions to Achieve Therapeutic Goals for Patients with Myelofibrosis
Click the"View Activity" button to view this activity.
View ActivityCME/CE is no longer available for this activity
When it comes to treating your patients with myelofibrosis (MF), are you applying the latest guidance in practice? Evidence shows that it takes an average of 17 years for evidence to change practice but how can we incorporate treatment advances to improve patient outcomes today? This activity looks to bridge the chasm between education and implementation by framing available evidence and guideline recommendations for MF, including diagnosis, risk stratification, JAK inhibition, monitoring response to therapy, and patient education strategies, into routine clinical practices that can be easily adapted by practices of varying size and resources. Through this activity, learners are provided the resources and tools needed to optimize risk and symptom assessment, as well as treatment selection, for patients with myelofibrosis.
This activity is intended for hematologists/oncologists and other members of the multidisciplinary clinical management team practicing in both community and academic hospital settings and private practice.
Myelofibrosis (MF) is a rare myeloproliferative neoplasm that has a poor prognosis, mostly due to leukemic transformation. Several novel approved therapies have shown efficacy in controlling symptoms of MF, improving patient quality of life, and extending overall survival. For patients to achieve therapeutic goals, clinicians must optimize treatment selection considerate of patient risk, monitor when to switch therapies, and mitigate the impact of disease symptoms and adverse events on patient quality of life. Given the rarity of MF and the rapid advances in risk assessment and therapy selection, clinicians require education on available data, coring systems, and evidence-based recommendations.
Upon completion of this activity, learners will be able to:
- Describe the role of risk stratification for guiding treatment selection in myelofibrosis (MF)
- Implement appropriate and timely risk-adapted treatment strategies following a diagnosis of MF
- Discuss guideline-recommended monitoring response strategies to determine treatment success or failure in patients with MF
Provided by the Academy for Continued Healthcare Learning (ACHL).
Supported by an educational grant from CTI BioPharma Corp., a Sobi company.
Brady Stein, MD, MHS
Professor of Medicine
Department of Hematology/Oncology
Northwestern University Feinberg School of Medicine
Chicago, IL
Professor of Medicine
Department of Hematology/Oncology
Northwestern University Feinberg School of Medicine
Chicago, IL
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships within 24 months (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with all ineligible companies. All relevant financial relationships have been mitigated prior to this activity.
Brady Stein, MD, MHS (faculty) has no financial relationships to disclose.
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: None
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The content for this activity was developed independently of any ineligible company. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor(s).
This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
This activity will take approximately 60 minutes to complete. To receive credit, learners are required to complete the pretest, view the online activity, and complete the posttest and evaluation. To receive credit, 75% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physician assistants, nurse practitioners, and nurses may participate in this educational activity and earn a certificate of completion as AAPA, AANP, and ANCC accept AMA PRA Category 1 Credits™ through their reciprocity agreements.
